Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Fast optoacoustic mesoscopy, using the skin as a window for therapeutic monitoring of local and systemic disease. (WINTHER)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Partnership: Photonics (cPPP)
Countries involved: Italy,Germany,France,United Kingdom
Call: Application driven Photonics components (H2020-ICT-2019-2, 2019)
Start date: 2020-01-01
End date: 2024-12-31
Duration (months): 60.0
Total project cost (EUR): 5111203.75
EU funding (EUR): 4292170.0
Participants: 5
Project status: SIGNED

Optoacoustic (photoacoustic) imaging dramatically improves upon conventional bio-optic barriers and enables three-dimensional, high-resolution optical imaging deep inside tissues (several mm to cm). Clinical optoacoustic macroscopy has been supported by two ERC Advanced Awards (2008, 2016; Prof. Ntziachristos). In parallel, under the ICT program INNODERM, we developed mesoscopic optoacoustic imaging for dermatology diagnostics. Termed raster-scan optoacoustic mesoscopy (RSOM), the method can image previously invisible ❶ pathophysiological/oxygenation and ❷ morphological features of the skin at depths of 1-5mm. RSOM has already shown clinical diagnostic value in dermatology and, fuelled by INNODERM, has been commercialised and globally placed by iThera Medical. WINTHER builds on this success. While INNODERM focused on diagnostic dermatology, it has become apparent that RSOM can also assess progression and therapy not only in skin but also in cardiovascular diseases and diabetes. However, to achieve this, RSOM should be able to assess endothelial function, ability that it is not yet available. WINTHER will build next-generation fast RSOM (F-RSOM), operating up to two orders of magnitude faster than state-of-the-art RSOM, enabling it to assess not only ❶,❷ above but also ❸ endothelial function. Using the skin as a window for disease assessment and aided by a modern computation framework, based on deterministic and artificial intelligence algorithms, F-RSOM aims to improve the clinical accuracy of RSOM and shift the paradigm in therapeutic monitoring of cardio-metabolic diseases and inflammatory skin conditions, strengthening Europe's leadership in photonics and in personalized medicine. The project is driven iThera Medical with a strong history of commercializing optoacoustics for clinical applications, by leading physicians (TUM, HUNIMED), and by RSOM, RSOM components and data analysis experts (TUM, iThera, Rayfos, Sonaxis).

Keywords: raster scan optoacoustic mesoscopy,handheld,label free,microvasculature,monitoring
Wooden structured telecommunications tower for the complete mobile network coverage (Wooden Tower)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Finland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In Europe and globally, the use of wireless communication in 4G and 5G networks is growing, resulting in the need for several thousands of new telecommunication towers (ground based towers ie. GBTs) annually. For serving the antenna and device technology and for answering the requirements of cities, operators and changing climate, the lifecycle of telecommunication infrastructure, its characteristics and appearance needs to be re-modified. Ecotelligent addresses the business opportunity by introducing to the market Ecopol, the small carbon footprint telecom tower, based on the application of the science of wood construction technology. Ecopol’s environmental impact is less than half of the equivalent steel GBTs. First 30 and 40 meter high Ecopol prototypes for 3G and 4G technologies are located in Hungary. Ecotelligent’s first target market are the 51 000 GBTs needed by 2023 in the European market. The first targeted customers are operators and tower companies. Other customers are mobile network operators and other owners of passive infrastructure where mobile network devices are installed onto. In 2023 Ecotelligent aims at selling Ecopol in 7 European countries, generating a cumulative turnover of over 27 million euros. Ecotelligent’s goal is to be the first wooden tower provider on the market offering low carbon, easy to retail alternatives and contribute to pleasant living environment. Ecotelligent’s team has long-term experience in telecommunication infrastructure design, construction and maintenance businesses, start-ups and fund-raising; extensive networks and good market knowledge. The goal of the proposed project is to strengthen market knowledge, customer and stakeholder contacts; outline further product and service development needs and update business plan and IPR strategy. EcoTelligent aims at utilising the SME Instrument Phase 2 funding for financing the further development and market entry activities.

Keywords: wood construction,antenna tower,telecommunications tower,carbon sink,co2 footprint,mobile network,aesthetic,urban planning,smart city
Novel Biomaterial for Improved and Cost-efficient Wound Healing (BIOCURE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Ireland,Ireland,Norway
Call: SME boosting biotechnology-based industrial processes driving competitiveness and sustainability (H2020-SMEINST-2-2015, 2015)
Start date: 2016-02-01
End date: 2018-07-31
Duration (months): 30.0
Total project cost (EUR): 1865625.0
EU funding (EUR): 1305937.5
Participants: 3
Project status: CLOSED

Wound treatment is a major healthcare cost for all developed countries. The global market for advanced wound care products was projected to be $ 3 billion in 2012, with an annual growth above 10% and representing one of the leading medical product sectors. However, this represents only some 15-20% of the overall cost of wound treatment, where hospitalisation and nurse time represent the remaining costs. BIOVOTEC aims to pursue a major market opportunity by developing a novel biomaterial based cost-effective wound dressings that can be used for initial treatment of all wounds at risk of delayed or non-healing, reducing the incidence of chronic wounds. BIOCURE range products will be safer, potentially more effective, much more easily scalable and significantly lower in cost when compared with the available advanced wound healing products. BIOCURE is an opportunity for BIOVOTEC to enter the world-wide advanced wound care market and maintain the European competitive position in the growing biotech and wound management sector. The accomplishment of the project objectives will thus represent a significant business opportunity for the two SMEs, with expected sales of over €50 million within 5 years of launch (i.e. 2022). Furthermore, BIOCURE will positively impact clinicians and patients through early stage treatment or resolution of chronic wounds and payers through reduced treatment costs per wound.

Keywords: wound care,venous leg ulcers,biomaterial,egg shall membrane,clinical validation,ce marking,industrial processes
European Training Network on Antiviral Drug Development (ANTIVIRALS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Austria,Germany,Germany,Belgium,Belgium,France,Netherlands,Netherlands,Netherlands,United Kingdom,Luxembourg
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) (H2020-MSCA-ITN-2014, 2014)
Start date: 2015-03-01
End date: 2019-09-30
Duration (months): 55.0
Total project cost (EUR): 3837214.41
EU funding (EUR): 3837214.4099999997
Participants: 13
Project status: CLOSED

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens. Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development. The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary. ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry. Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.

Keywords: antivirals,picornavirus,coronavirus,dengue,chikungunya virus,hepatitis b virus,small molecule inhibitors,alphabodies,structure based drug design,ligand based drug design
Co-Evolving City Life (CoCi)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Switzerland
Call: ERC Advanced Grant (ERC-2018-ADG, 2018)
Start date: 2020-10-01
End date: 2025-09-30
Duration (months): 60.0
Total project cost (EUR): 2499500.0
EU funding (EUR): 2499500.0
Participants: 1
Project status: SIGNED

How could networks of innovative cities contribute to the solution of humanity’s existential problems? Given the on-going digital revolution and our present-day sustainability challenges, we have to reinvent the way cities are operated. We propose that the requirement of organizing cities in a more resilient way implies the need for more decentralized solutions, based on digitally assisted self-organization, and that this concept is also compatible with sustainability requirements and stronger democratic participation. The CoCi proposal will investigate, whether such a decentralized, participatory approach could compete with a fully centralized approach in terms of efficiency and sustainability, or perform even better than that. This requires in particular to figure out, how distributed co-creation processes can be coordinated and lifted to a professional level in a scalable way. The main questions of the CoCi proposal are: How could more participatory smart cities work, and how can they meet the requirements of being more efficient, sustainable and resilient? What are their risks and benefits compared with centralized approaches? How could digital societies fitting our culture, for example, based on values such as freedom, equality and solidarity (liberté, égalité, fraternité) look like, and what performance can be expected from them? The CoCi proposal brings together two research directions: first, the automation of mobility solutions based on the Internet of Things and Machine Learning approaches, as they have been pursued within the “smart cities” paradigm and, second, novel collaborative approaches as they have been recently discussed under labels such as participatory resilience, digital democracy, City Olympics, open source urbanism, and the “socio-ecological finance system”.

Keywords: computational social science,complexity science,global systems science
Development of a new CRISPR-Cas3-based tool for large genomic deletions (GenDels)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,United States
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-07-01
End date: 2022-06-30
Duration (months): 36.0
Total project cost (EUR): 264669.12
EU funding (EUR): 264669.12
Participants: 2
Project status: CLOSED

The advent of the revolutionary genome editing technique CRISPR-Cas9 has enabled targeted gene mutation, repression, and activation, facilitating impactful biological findings. However, Cas9 as an unbiased DNA deletion tool is limited in its ability to interrogate large regions of DNA of unknown function, because it predominantly generates very small (<20 bp) insertions and deletions at its target site. The capacity to rapidly and efficiently generate large genomic deletions does not currently exist and would be an extremely useful tool for research, allowing for rapid strain engineering of bacterial cells for synthetic biological and metabolic engineering purposes. Additionally, this technology would allow for the interrogation of large segments of non-coding DNA in human cells, much of which has unknown function, but whose variants are often associated with human disease. In this proposal, I aim to develop a Type I-C CRISPR-Cas system employing the Cas3 enzyme (completely distinct from Cas9), which naturally possess coupled nuclease and helicase activity, for high-throughput gene-editing purposes in various prokaryotic, as well as human cells. My preliminary results have shown that this is a credible approach, as I have been able to generate individually, as well as in combination, multiple deletions in bacterial organisms exceeding 60 kb in size. A focal point of the proposal is to adapt this system for use in human cells, which would provide a novel basic research tool with unprecedented capabilities and also could be utilized in human health-related applications. The proposal aims to address this later possibility by utilizing the developed system to treat human cell lines infected with difficult-to-treat pathogenic viruses.

Keywords: crispr cas3,genetic engineering,viral defense
Non-thermal treatment to delay the onset of honey crystallization (LIQUAM)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: SME instrument
Countries involved: Spain
Call: Resource-efficient eco-innovative food production and processing (H2020-SMEINST-1-2014, 2014)
Start date: 2015-03-01
End date: 2015-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Honey crystallizan is a natural phenomenon by which honey turns from liquid to a semi-solid state obtaining cloud, thick and grainy. Nearly all honey crystallizes, some while still in the comb, others within a few days, weeks or months after being extracted. Honey crystallization is little understood by the consuming public. Many consumers assume incorrectly that crystallized honey is spoiled or has been adulterated and they either not purchase it or discard it. Other consumers directly prefer liquid honey. To delay the onset of crystallization large packers pasteurize honey destined to retail. During pasteurization, honey is heated up to 80ºC for 1-2 minutes to melt glucose micro-crystals which act as nuclei which are the essential starting points for the formation of crystals. Raw honey contains natural vitamins, minerals, antioxidants and nutrients that are beneficial to our health however during pasteurization all are destroyed turned honey to a much poor product. The goal of LIQUAM is to offer a non-thermal alternative to delay the onset of honey crystallization whilst retaining the quality attributes of raw honey by applying High Power Ultrasound (HPU) with the aim of replace thermal pasteurization process. HPU is a superior and more energy efficient alternative to existing thermal pasteurization methods. Ultrasonic processing is establishing itself as a significant food-processing technology with the capability for large commercial scale-up and good payback on capital investment. The technology was demonstrated by applicants at small scale reaching honey treatment rates of 75kg/h. However have to be scale-up to reach production rates typically used in the industry of around 1,000kg/h. The objective of this phase 1 is to complete a feasibility study to find out the workability and profitability of the business venture. If the result of the feasibility study is positive, we will write the Business Plan and we will apply to phase 2.

Keywords: honey,quality attributes,cristallization
Nutritious, safe and sustainable seafood for consumers of tomorrow (SEAFOODTOMORROW)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Cross-cutting marine and maritime research
Action type: Innovation actions
Countries involved: Italy,Italy,Spain,Germany,Spain,Spain,Spain,Spain,Ireland,Italy,Austria,Türkiye,Lithuania,Belgium,Poland,Norway,Poland,Norway,Hungary,Sweden,Belgium,Greece,France,France,France,France,France,Czechia,Netherlands,Denmark,United Kingdom,United Kingdom,Portugal,United Kingdom,United Kingdom,Portugal,Portugal
Call: Innovative sustainable solutions for improving the safety and dietary properties of seafood (H2020-BG-2017-1, 2017)
Start date: 2017-11-01
End date: 2021-04-30
Duration (months): 42.0
Total project cost (EUR): 7520196.91
EU funding (EUR): 6996032.25
Participants: 49
Project status: CLOSED

SEAFOODTOMORROW aims to validate and optimize commercial solutions for improving the socioeconomic and environmental sustainability of the seafood production and processing industry, while contributing to product quality and safety. Activities will focus on the sustainable production and processing of nutritious and safe seafood products through the demonstration and first application in the market of eco-innovative, sustainable solutions of marine and aquaculture-derived food products and nutrients. The proposal will take into account impacts across different regions and population segments, as well as the specificities of different types of seafood. Activities will include among others: utilization of agro and seafood byproducts to develop sustainable feeds for aquaculture enabling the production of tailor made products fortified with specific essential nutrients for consumers, assess the feasibility of salt replacers in seafood, validate digestible, attractive, functional and nutritionally adapted seafood for senior people and youths, validate strategies to prevent/remove contaminants from seafood, and optimize sensors and biosensors for the assessment of safety, among others. The consortium expects strengthening the wider utilization of eco-innovative solutions, as a result of greater user acceptance, higher visibility of these innovative solutions and creation of scalable markets, and increasing the availability of healthier seafood to improve consumers' diet and health. The consortium is built on interdisciplinary research teams of 19 RTDs involved, renowned by its top-quality applied technological development and with strong and cohesive links gathered in previous funded activities (e.g. FP7 ECsafeSEAFOOD), thus anticipating successful outcomes. In addition, 4 IAGs and 13 SMEs with diverse and complementary interests in the solutions under validation and optimization will also integrate the consortium.
Candidate mutation discovery in early-flowering mutants 'Rojo Pasión Precoz' and 'Bulida Precoz' (PrunMut)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-09-01
End date: 2021-08-31
Duration (months): 24.0
Total project cost (EUR): 171460.8
EU funding (EUR): 171460.8
Participants: 1
Project status: CLOSED

Whole-genome sequencing using novel Next Generation Sequencing (NGS) technologies allows to mine for induced genomic or transcriptomic differences in non-model plant species, and is providing a universal and generic platform for the isolation of genes including spontaneously mutated loci important for breeding or biotechnological applications. Moreover, two spontaneous early-flowering apricot mutants ‘Rojo Pasión Precoz’ and ‘Búlida Precoz’ have been recently discovered in Southern Spain, derived from commercial cultivars. This unique plant material represents an excellent opportunity for deciphering the basis of early-flowering in apricot and to speed up the long-term breeding process for precocity as there is need to introgress other traits. PrunMut is aimed at (1) generating genomic resources for the identification candidate casual mutation in the two apricot mutants ‘Rojo Pasión Precoz’ and ‘Búlida Precoz’, also useful apricot breeding programs; (2) identifying candidate causal mutations of early flowering in the two mutants and shed light on mutation rate in this species; (3) evaluating the impact of the candidate casual mutation and give cues on the control of flowering date in the two mutants and (4) transfer of result for breeding and functional genomics. To develop markers for Prunus breeding programs aimed at early/late flowering date and to build collaborations for future functional genomics validation.

Keywords: mutation,bioinformatics,transcriptomics,flowering date,prunus